Skip to main content
ICU logo

ICU · SeaStar Medical Holding Corp · Earnings Call Transcripts & Audio

Track ICU — free
$3.13 +0.03 (+0.97%) At close · Sep 10
Market Cap
$13.79M
Shares
4.41M

SeaStar Medical Holding Corp Earnings Call Transcripts

Quarterly earnings calls for SeaStar Medical Holding Corp (ICU), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Earnings call
FY26 · Q2
2026-08-12
SeaStar Medical Holding Corp (ICU) Q2 2026 Earnings Call Transcript
Confident tone QUELIMMUNE pediatric commercial adoption NEUTRALIZE-AKI pivotal trial enrollment Adult AKI market opportunity and FDA pathway
Revenue
$615,000
▲ 82% YoY
Gross margin
91.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-13
SeaStar Medical Holding Corp (ICU) Q1 2026 Earnings Call Transcript
Confident tone Quellimmune pediatric commercial momentum Neutralize AKI pivotal trial enrollment SCD platform broader indications
Revenue
$495,000
▲ 68.9% YoY
Gross margin
90.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-25
SeaStar Medical Holding Corp (ICU) Q4 2025 Earnings Call Transcript
Confident tone Pediatric AKI Commercial Expansion (Qualimmune) Neutralize AKI Pivotal Trial Enrollment (Adult AKI) SAVE Registry Publication and Clinical Evidence
Revenue
$420,000*
▲ 526.9% YoY
Gross margin
97.1%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-13
SeaStar Medical Holding Corp (ICU) Q3 2025 Earnings Call Transcript
Confident tone Neutralize AKI pivotal trial enrollment Quellimmune commercial launch and pediatric site activation Neutralize CRS cardiorenal syndrome trial
Revenue
$183,000
▲ 169.1% YoY
Gross margin
92.3%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-14
SeaStar Medical Holding Corp (ICU) Q1 2025 Earnings Call Transcript
Confident tone QUELIMMUNE pediatric commercial launch NEUTRALIZE-AKI adult pivotal trial Cardiac surgery breakthrough device designations
Revenue
$293,000
Diluted EPS
$-4.40
Gross margin
100.0%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-27
SeaStar Medical Holding Corp (ICU) Q4 2024 Earnings Call Transcript
Confident tone Quellimmune commercial launch NeutraLized AKI pivotal study Pipeline expansion opportunities
Revenue
$67,000*
Gross margin
100.0%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-12-04
SeaStar Medical Holding Corp (ICU) Q3 2024 Earnings Call
Revenue
$68,000
Diluted EPS
$-11.00
Gross margin
100.0%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-15
SeaStar Medical Holding Corp (ICU) Q2 2023 Earnings Call
Diluted EPS
$-41.00
Audio Transcript Slides 8-K10-Q
Showing 1–8 of 8 earnings calls
Key facts CIK 1831868 CUSIP 81256L302 13F (30d) 11 filings 11 filers Visit website Investor relations